Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 17/20 | 0.66 |
| ▸ | ERBB2 | P04626 | 3/20 | 0.61 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.61 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.61 |
| ▸ | KDR | P35968 | 3/20 | 0.60 |
| ▸ | SRC | P12931 | 1/20 | 0.60 |
| ▸ | DRD2 | P14416 | 1/20 | 0.60 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.59 |
| ▸ | FLT1 | P17948 | 1/20 | 0.59 |
| ▸ | FLT4 | P35916 | 1/20 | 0.59 |
| ▸ | EPHA2 | P29317 | 2/20 | 0.58 |
| ▸ | EPHB4 | P54760 | 2/20 | 0.58 |
| ▸ | GAK | O14976 | 1/20 | 0.58 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.58 |
| ▸ | LYN | P07948 | 1/20 | 0.58 |
| ▸ | RET | P07949 | 1/20 | 0.58 |
| ▸ | EPHA1 | P21709 | 1/20 | 0.58 |
| ▸ | ERBB3 | P21860 | 1/20 | 0.58 |
| ▸ | EPHB2 | P29323 | 1/20 | 0.58 |
| ▸ | EPHA5 | P54756 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3123455 | 0.90 | EGFR (0.65) | EGFRERBB2KCNH2CYP2D6KDR | |
| SCHEMBL13324987 | 0.89 | EGFR (0.80) | EGFRERBB2KCNH2EPHA2EPHB4 | |
| SCHEMBL3136293 | 0.88 | EGFR (0.85) | EGFRERBB2KCNH2CYP2D6KDR | |
| SCHEMBL3131165 | 0.84 | EGFR (0.75) | EGFRERBB2KDRSRCDRD2 | |
| SCHEMBL3133516 | 0.83 | EGFR (0.77) | EGFRERBB2KDRSRCDRD2 | |
| SCHEMBL5210047 | 0.81 | EGFR (0.85) | EGFRERBB2KCNH2EPHA2EPHB4 | |
| SCHEMBL18012881 | 0.80 | EGFR (0.73) | EGFRERBB2KDRSRCDRD2 | |
| SCHEMBL13052266 | 0.80 | EGFR (0.82) | EGFRERBB2EPHA2EPHB4GAK | |
| SCHEMBL3123549 | 0.80 | EGFR (0.93) | EGFRERBB2KCNH2CYP2D6KDR | |
| SCHEMBL3132716 | 0.80 | EGFR (1.00) | EGFRERBB2KCNH2CYP2D6KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130005727-A1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2013-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130005727-A1 | QUINAZOLINE DERIVATIVES | ABL1, ERBB2, EGFR | EGFR 3/4885ERBB2 2/4885KCNH2 1875/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.